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Abstract 
Objectives 
HIV-positive people have increased risk of infection related and infection unrelated 
malignancies (IRM/IURM). To determine the impact of aging on future IRM and IURM 
incidence is yet to be determined.  
Methods 
People enrolled in EuroSIDA followed from the latest of first visit or 01/01/2001 until 
last visit or death. Poisson regression investigated the impact of aging on the incidence of IRM 
and IURM adjusting for demographic, clinical and laboratory confounders. Linear exponential 
smoothing models forecasted future incidence. 
Results 
15648 people contributed 95033 person years, 610 developed 643 
malignancies(IRM:388[60%], IURM:255[40%]). After adjustment, higher IRM incidence was 
associated with lower CD4 count (CD4 <200:3.77[2.59,5.51]; compared to 500+ cells/mm3) 
independent of age,  while  CD4<200 was associated with IURM in people aged<50 years only 
(2.51[1.40-4.54]). Smoking was associated with IURM (1.75[1.23,2.49]) compared to never-
smokers in people≥ 50 years only, and not with IRM.  Both IURM and IRM incidence increased 
with older age. It is projected that the incidence of IRM will decrease by 29% over a 5-year 
period from 3.1([1.5-5.9]/1000person-years) in 2011, whereas IURM incidence will increase by 
44% from 4.1([2.2-7.2]/1000person-years) over the same period.   
Conclusion 
Demographic and HIV-related risk factors for IURM (aging and smoking) and IRM 
(immunodeficiency and ongoing viral replication) differ markedly  and the contribution from 
IURM relative to IRM will continue to increase due to aging of the HIV population , high 
smoking and lung cancer prevalence  and low prevalence of untreated HIV-infection. These 
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findings suggest the need for targeted preventive measures and to evaluate cost-benefit of 
screening for IURM in HIV populations.  
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Introduction  
HIV-positive people are at increased risk of many malignancies compared to the 
general population(1, 2), however the exact mechanisms are poorly understood(3). Increased 
risk could be due to high prevalence of traditional cancer risk factors such as smoking(4) and 
alcohol use(5). However, co-infection with other pro-oncogenic viruses(6), 
immunodeficiency(2),(7), activated inflammation and coagulation(8), potential direct pro-
oncogenic effect of HIV and combination antiretroviral therapy (cART) toxicity (3) may also 
contribute. The introduction of cART in 1996 lead to restored immune function, reduced 
incidence of AIDS-defining malignancies (ADM)(9-11) and increased survival(12) . As a result, 
the burden of cancers in the HIV-positive population traditionally associated with older age is 
becoming increasingly important. There is a growing need to address the changing 
epidemiology of cancers as the population ages. This has been addressed through several 
studies from the USA(1, 13), however research in the European population is needed. 
 
The burden of non-AIDS-defining malignancies (NADM) is now surpassing that of ADM 
in HIV-positive people in the USA and Europe(1, 13). Furthermore, some NADM occur more 
frequently than ADMs in HIV-positive people, for example, more cases of anal cancer and 
Hodgkin lymphoma are diagnosed than invasive cervical cancer(1, 14). For these reasons 
recent research has shifted towards defining malignancies according to infection related (IRM) 
and infection unrelated (IURM)(8). 
 
The changing epidemiology of malignancies and the impact of aging on cancer 
incidence needs to be better characterised. The aim of this study was to investigate the impact 
of aging in HIV-positive people on the incidence of IRM and IURM within EuroSIDA, a large 
European cohort of HIV-positive people with a long follow-up period and to estimate the likely 
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impact of IRM and IURM in the HIV-positive population in the next 5 years for future 
healthcare planning, treatment and prevention.
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Patients and methods 
EuroSIDA study 
EuroSIDA is a prospective observational open cohort of 18,587 HIV-1 positive patients 
in 108 centres across 33 European countries, Israel and Argentina (details at www.cphiv.dk). 
Patients were enrolled into 9 cohorts from May 1994 and informed consent was obtained from 
all patients. All information is prospectively collected via standardised forms which are 
completed by personnel at the sites at the time of enrolment and every 6 months thereafter. 
The forms collect basic demographic, clinical and laboratory data, including all CD4 counts and 
HIV viral-loads (HIV-VL), starting and stopping dates of all antiretroviral drugs, smoking status, 
and dates and diagnoses of all new AIDS-defining diagnoses (using the 1993 CDC clinical 
definition(15), includes ADMs) since last follow-up. In 2001, the standardised forms were 
updated to collect data on all new non-AIDS-defining diagnoses identified by clinical diagnosis 
or autopsy (including NADM) (16) allowing the sites to report date of diagnosis, method of 
diagnosis (definitive, presumptive, autopsy), and location (selected from a list of common 
malignancies or as free text). All reported AIDS and non-AIDS defining malignancies were 
source verified against case notes at the sites by members of the coordinating office to ensure 
data accuracy, as well as for all other major clinical events and a random sample of 10% of all 
other patients. Loss to follow-up in EuroSIDA is <5% per 100 PYFU and consistent over 
time(17).  
 
Inclusion criteria 
All subjects enrolled in EuroSIDA with prospective follow-up after 1 January 2001 were 
included. Patients were followed from the later of first visit or 1 January 2001 until last visit or 
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death. Median date of last visit was March 2012 (Interquartile range [IQR] August 2009-June 
2012).  
 
All malignancies, both AIDS-defining and non-AIDS, diagnosed during the follow-up 
period  were included and classified using the International Classification of Diseases and 
Related Health Problems, 10th edition code classification system(18). Multiple malignancies 
per person were included, however pre-existing cancers, secondary diagnoses, metastasis, and 
reoccurrence of the same malignancy type, pre-cancers and non-melanoma skin cancers were 
excluded. IRMs were defined as all malignancies with a probably infectious cause:  Kaposi’s 
sarcoma (KS) (caused by human-herpesvirus8 [HHV8]), non-Hodgkin lymphoma (NHL) and 
Hodgkin lymphoma (HL) (Epstein-Barr virus [EBV]), invasive cervical cancers (ICC), selected  
malignancies of the head and neck (Base of tongue, pharynx, tonsils), anus, penis, vulva and 
vagina(Human papilloma virus [HPV]), liver (Hepatitis B [HBV] and C[HCV]) and stomach (H. 
pylori]) (19).  All remaining malignancies were defined as IURMs. 
 
Statistical methods 
Poisson generalised estimating equations assuming auto-regressive (AR1) correlation were 
used to estimate the association between age and IRM and IURM incidence. Models were 
adjusted for baseline (ethnicity, region, gender and mode of transmission[Homosexual, male 
IDU, female IDU, male heterosexual, female heterosexual, missing], BMI) and time-updated 
(age, calendar year, smoking status [current, previous, never, missing], current HIV-VL plasma 
levels, CD4 cell count, prior HBV [Prior positive HBsAG  surface antigen test or presence of 
detectable HBV DNA] andHCV [prior positive HCV surface antibody test or presence of 
detectable HCV RNA] co-infection, prior diagnoses of ADM, NADM, AIDS-defining [excluding 
ADM],  and non-AIDS-defining events [defined as cardiovascular, end-stage renal disease, liver 
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failure and pancreatitis, excluding NADM](16), cART use [antiretroviral regimen containing ≥3 
drugs from any class], and regimen according to intention to treat: PI/NNRTI-based) variables.  
 
It was decided a priori to stratify associations between IRM and IURM with CD4 cell 
count and smoking status by age (<50 and ≥50 years) due to strong associations with both age 
and cancer risk. Interactions between age and all other variables were also investigated.  
 
The proportion of excess malignancies within our cohort attributable to each 
significant modifiable factor and age were calculated using an internally valid version of the 
population attributable risk in the presence of confounding(20).  This is interpreted as the 
percent of excess malignancies attributable to each factor relative to a reference category, 
within the cohort.  
 
Future crude IRM and IURM biannual incidence was forecast using linear exponential 
smoothing models, stratified by baseline age group (<50, ≥50 years), CD4 (<350, ≥350 
cells/mm3), HIV risk group and smoking status. Forecasts were restricted to those enrolled 
prior to 2001. This ensures a stable population over time (i.e. no new recruitments), however 
people were allowed to leave the cohort i.e. death or loss to follow-up. No further adjustments 
for covariates were made.  
 
All statistical tests were two sided and a type I error rate of 5%. All statistical analyses 
were performed using SAS 9.3 (Statistical Analysis Software, Cary NC, USA). 
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Results 
Characteristics 
15,648 persons contributed 95,033 PYFU with a median follow-up of 6.0 (Interquartile range [IQR]:2.5,10.7) 
years. Baseline characteristics according to malignancy status are shown in Table 1.   At baseline 16.0% were aged 
over 50, 72.6% of the population were male, 88.3% were of white ethnic origin and 38.7% of men were infected with 
HIV through homosexual exposure. Approximately one third of patients were current smokers and one third had 
never smoked. The median CD4 at baseline was 410 (IQR:265,588) with 14.8% having  CD4200 cells/mm3 and HIV-
VL was 123 (IQR: <50,5200) with 54.5% having HIV-VL  400 copies/mL. There were 24.4% and 1.9% of patients who 
had a prior AIDS and non-AIDS defining event respectively. Co-infection with HCV and was HBV was prevalent in 
23.1% and 5.5% of people.   
 
610 people developed 643 malignancies, of which 60.3% were IRM and the remaining 39.7% were IURM 
(See Table 2Error! Reference source not found.). The most common IRMs were NHL(N=116), Anal cancer(85), KS(62) 
and HL(43). Cancers of the lung(N=55), prostate(28), colorectal(23) and breast(22) were common IURMs. At 
diagnosis, those who developed IURMs relative to IRM were older (Median age: [IURM] 54 IQR:46,61 vs [IRM] 46 
IQR:39,52 years) had a higher CD4 (446 IQR:295,608 vs 342 IQR:182, 546) and lower HIV-VL(<50 IQR:<50,86 vs 61 
IQR:<50,20002). A higher proportion had prior HCV co-infection and proportion of prior HBV co-infection was similar. 
Proportions of ever smokers in IRMs (45%) and IURMS (46%) were similar.  The majority of cancers diagnosed in 
those younger than 50 (N=353 cancers) were IRM (75%), with 31% EBV related and 25% HPV related. In those older 
(290 cancers), more than half were IURM (57%), accounting for 13% lung cancers  and 10% prostate cancers. 
 
Adjusted Incidence of IRM and IURM 
In adjusted models, those aged over 50 had 1.62 (95%CI:1.14,2.30) times higher IRM incidence compared to 
those aged 36-40 years (Table 3), corresponding to a 17% higher incidence per 10 years older age (aRR:1.17; 
1.05,1.32). The % of excess IRM attributable to being aged over 50 compared to 36-40 years was 12%. Factors 
strongly related to high IRM incidence were HIV associated. Specifically, elevated HIV-VL>400 was associated with 
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higher IRM incidence (1.84; 1.39,2.43, P<0.01) and accounted for 19% of excess malignancies, relative to those with 
well controlled viraemia (HIV-VL of 400 or less). Lower current CD4 cell count was associated with higher IRM 
incidence (Table 3), which was similar in those aged ≤ 50 and over 50 years(figure 1C P interaction=0.82). A CD4<200 
and 200-349 cells/mm3 accounted for 21% and 11% of excess IRMs respectively (Table 3) relative to those with a CD4 
cell count of 500 or higher. There was no association between IRM incidence and current smoking (Table 3) in 
younger or older people (figure 1D; P for interaction=0.31). Prior HBV-co-infection was associated with higher IRM 
incidence (aRR:1.70; 1.24,2.32), but only 5% of IRM were attributable to HBV co-infection within the cohort (Table 
3). 
 
IURM incidence was 7.33 (95%CI: 4.07,13.21;P<0.01) and 2.37 (1.31,4.27;P<0.01) fold higher in those aged 
over 50 and aged 41 – 50 years compared to those aged 36 – 40 years (Table 3), and explained 56% and 17% of 
excess IURMs within the cohort respectively. This corresponds to a two fold increase in IURM incidence per 10 years 
older age (aIR:2.07;95%CI:1.84,2.32). Current smoking was associated with elevated IURM incidence and explained 
16% of IURMs overall. Stratifying by age, IURM was elevated in current smokers relative to non-smokers in those 
aged over 50 (aIRR: 1.75; 1.23,4.49;P<0.01; figure 1B), but not in those aged ≤50 (aIRR: 1.12; 0.71,1.77;P=0.51), 
although the p-value of the interaction term was non-significant (P=0.32). Current smoking was not associated with 
IURM incidence after exclusion of lung cancers. A low current CD4 count was associated with higher IURM incidence 
(CD4<200 aRR:1.99; 1.26,3.17;P<0.01, relative to CD4>500 cells/mm3). Despite this, the overall excess of IURMs 
attributable to a CD4<200 cells/mm3 (6%) were small. The association between higher IURM incidence and low CD4  
was evident in those aged <50 years (aRR:2.52; 1.40,4.54; P,0.01, figure 1A), but not in those aged>50 (aRR:1.14; 
0.62,2.12;P=0.56 figure 1A), although the p-value of the interaction term did not reach statistical significance 
(P=0.09). Prior HBV-co-infection was also associated with higher IURM incidence (aRR:1.73; 1.17,2.55;P<0.01), but 
only 5% were attributable to HBV co-infection within the cohort (Table 3).  
 
12 
 
12 
 
Future Incidence 
There were 6111 people enrolled prior to 1 January 2001 contributing 54030 PYFU (median of 11.1 (IQR: 5.8 
– 11.3 PYFU per person) who developed 243 IRM and 161 IURM during follow-up. At baseline 82% were aged under 
50, 78% were male and 41% had a CD4 count below 350. There were 47% were homosexual, 25% were heterosexual 
and 21% were IDUs. 26% were smokers at baseline, 21% were non-smokers at baseline and 52% had unknown 
smoking status.  
 
Assuming current trends continue, crude IRM incidence for those recruited before 2001 was forecast to 
decline from an incidence of 3.1(95%CI:1.5,5.9)/1000PYFU in Jul-Dec 2011 to 2.2(95%CI:0.9,4.3) after 5 years (Figure 
2A).This was consistent in all strata, with the exception of injecting drug users in which the incidence was stable (
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Table 4). Forecasted crude IURM incidence increased from 4.1(95%CI:2.2,7.2) Jul-Dec 
2011 to 5.9(95%CI:3.2,10.2) after 5 years Figure 2B, and was consistent in all strata, except 
never smokers for whom the IURM incidence was forecast to decrease from 1.7 
(95%CI:0.0,10.6) in Jul-Dec 2011 to 0.8 (95%CI:0.0,7.0) after 5  years (Table 4). The incidence of 
IURM surpassed that of IRM from January-June 2009 onwards, and is forcast to continue to 
increase over the subsequent 5 years. 
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Discussion 
 Demographic and HIV-related risk factors for IURM and IRM differ markedly. 
The incidence of IURM has exceeded that of IRM since January-June 2009 (in those enrolled in 
EuroSIDA prior to 2001) and the contribution from IURM is forecast to increase  over the 
subsequent 5 years  due to aging of the HIV population, high smoking prevalence(4), and low 
prevalence of untreated and advanced HIV-infection. These findings suggest the need to 
develop targeted preventive measures and evaluate cost-benefit of screening for IURM in HIV 
populations. Ours is one of the few large prospective studies in a European population with 
free access to care. The majority of the research to date has focussed largely on patients 
within the USA. 
 
IRM incidence was highly associated with traditional HIV factors such as higher HIV-VL 
and lower CD4 cell count, and to a lesser extent, age. The incidence of IRM steadily increased 
with lower CD4 cell count category.  However the proportion of IRM attributable to older age, 
higher HIV-VL and lower CD4 were similar to each other in EuroSIDA, due to ongoing aging and 
low prevalence of uncontrolled HIV-infection in this cohort. Those aged 51 or older may have 
had longer exposure to oncogenic viruses which could explain the increased IRM incidence.  
 
Older age was the largest contributor to IURM incidence. Our result of a two-fold 
higher IURM incidence for a 10 year increase in age is similar to findings of the SMART 
study(21) and to data published online by the European cancer observatory, which showed a 
1.9 fold increase in incidence of all malignancies in the general population(22). The effects of 
aging, including reduced immune function, are thought to be accelerated in HIV-positive 
populations and may also contribute to an increased IURM incidence(23).  
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Current smoking status was associated with higher IURM incidence, driven by lung 
cancer, in people aged over 50, likely reflecting lag time between smoking and the onset of 
consequences. As the proportion of the cohort aged over 50, 60 and 70 increases, the relative 
impact of characteristics associated with IURM risk is likely to continue to shift, highlighting the 
need for ongoing monitoring of the changing epidemiology of malignancies. This is a 
comparatively new research area in HIV and large, well designed observational studies are 
crucial to understand both existing and emerging comorbidities in HIV positive people. Higher 
IURM incidence was associated with a CD4 cell count <200 in people aged under 50 only, 
which appeared to be due to a relatively high number of lung cancers in this group. However, 
numbers were small and further investigation was not possible.  
 
The incidence of IRM was forecast to decline over time, likely driven by the low 
prevalence of advanced and untreated HIV infection, following improvements in treatment 
efficacy, uptake and adherence. Antiretroviral therapy controls HIV viremia leading to CD4 
recovery, and reduces the risk of some IRMs, such as KS and NHL(1, 11, 13, 14, 24), but not all 
(i.e. HL, ICC and anal cancers)(11, 24, 25) (26).  This was consistent in all strata except IDUs, 
who are less likely to be on treatment and have poorer outcomes. The incidence of IURMs was 
forecast to gradually increase in the near future, driven by aging of the HIV-positive 
population.  The only exception was in non-smokers, reflecting lower lung cancer rates and 
further supporting the need for cessation programs. Malignancy incidence in an American 
study was projected to increase by approximately 45% between 2010 and 2030, driven by 
malignant diagnoses in older age groups in the general population(27). A similar result was 
found for the UK population(28).  
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This study has a number of limitations. EuroSIDA has a relatively large number of 
prospectively collected source validated malignancies, but despite this, the frequencies of 
individual malignancies were small and could not be investigated or forecasted individually. 
Furthermore, this is an observational study and residual confounding cannot be ruled out. The 
predicted small increase in IURM may be influenced by changes in and uptake of cancer 
screening practices, such as cervical, breast, colorectal and prostate screening, in clinics. 
However, no significant changes in the incidence of these cancers occurred in our study, 
although numbers were small.  EuroSIDA does not routinely collect data on screening practices 
and therefore we cannot investigate the role of screening further. However, recent survey data 
on HIV management in active EuroSIDA sites found screening rates for cervical and anorectal 
cancers were low (29). Linear exponential smoothing models are a simple method of forecasting 
which assume the continuation of previous population trends. A limited amount of historical 
data was available for forecasting, contributing to uncertainty around forecasts. HIV-specific 
population projections are not currently available, which prevents the use of more advanced 
methodologies, such as age-period-cohort models.  
 
As the HIV population ages, the incidence of IURM is expected to increase due to aging 
of the HIV population and the high prevalence of lung cancer due to smoking, the effects of 
which generally manifest with longer-term exposure and thus at older ages. Conversely, IRM 
incidence is expected to decline due to the low prevalence of advanced and untreated HIV 
infection and severe immunodeficiency. IURM should therefore be a priority in the coming years 
as higher proportions of HIV positive people live past 50, 60 and 70. Studies evaluating cost-
benefit of screening-programmes for HIV-positive people and targeted preventive 
interventions, such as cessation programs for smoking and alcohol use, and vaccinations for 
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oncogenic viruses should be considered to reduce the burden of avoidable cancers in the long 
term.  
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Table 1 Baseline Characteristics of persons who have an infection related (IRM) and infection unrelated (IURM) malignancy during follow up  
  All participants 
IRM IURM 
Characteristics N (%)/ Median(IQR) 
Overall 15,648 (100.0) 374 (100.0) 247 (100.0) 
          
Categorical N (%)       
Age group       
  < = 35 years 5,419 (34.6) 78 (20.9) 18 ( 7.3) 
  36 - 40 years 3,337 (21.3) 93 (24.9) 40 (16.2) 
  41 - 50 years 4,390 (28.1) 133 (35.6) 78 (31.6) 
  51 + years 2,502 (16.0) 70 (18.7) 111 (44.9) 
          
Region3       
  Argentina 597 ( 3.8) 13 ( 3.5) 6 ( 2.4) 
  East 2,733 (17.5) 14 ( 3.7) 6 ( 2.4) 
  East central 2,041 (13.0) 40 (10.7) 25 (10.1) 
  West 3,220 (20.6) 97 (25.9) 71 (28.7) 
  North 3,332 (21.3) 86 (23.0) 63 (25.5) 
  South 3,725 (23.8) 124 (33.2) 76 (30.8) 
          
White ethnicity 13,821 (88.3) 331 (88.5) 228 (92.3) 
          
Risk group       
  Homosexual (Men only) 6,051 (38.7) 191 (51.1) 123 (49.8) 
  IDU (Male) 2,290 (14.6) 49 (13.1) 24 ( 9.7) 
  IDU (Female) 1,091 ( 7.0) 32 ( 8.6) 10 ( 4.0) 
  Heterosexual (Male) 2,178 (13.9) 35 ( 9.4) 32 (13.0) 
  Heterosexual (Female) 2,830 (18.1) 43 (11.5) 36 (14.6) 
  Other (Male) 910 ( 5.8) 20 ( 5.3) 16 ( 6.5) 
  Other (Female) 298 ( 1.9) 4 ( 1.1) 6 ( 2.4) 
Smoking status       
  Current 5,393 (34.5) 132 (35.3) 83 (33.6) 
  Previous 61 ( 0.4) 4 ( 1.1) 1 ( 0.4) 
  Never 5,030 (32.1) 104 (27.8) 66 (26.7) 
  Unknown 5,164 (33.0) 134 (35.8) 97 (39.3) 
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Prior AIDS1 (excluding ADM) 3,811 (24.4) 122 (32.6) 65 (26.3) 
Prior ADM   734 ( 4.7) 34 ( 9.1) 17 ( 6.9) 
Prior non-AIDS events2 (excluding NADM) 297 ( 1.9) 10 ( 2.7) 8 ( 3.2) 
Prior NADM   222 ( 1.4) 5 ( 1.3) 13 ( 5.3) 
Hepatitis B positive 868 ( 5.5) 38 (10.2) 23 ( 9.3) 
Hepatitis C positive 3,607 (23.1) 76 (20.3) 35 (14.2) 
          
On cART   11,946 (76.3) 304 (81.3) 215 (87.0) 
Numeric Median (IQR)       
CD4 (cells/mm3) 410 (265,588) 347 (200,523) 390 (259,546) 
Nadir CD4 (cells/mm3) 182 (76,303) 124.5 (47,250) 160 (70,255) 
HIV-VL (copies/ml) 123 (<50,5200) 772 (<50,18300) 88 (<50,1501) 
 
Baseline was defined as the latest of first visit or 01 January 2001. 
1 Defined by the1993 CDC clinical definition(15) 
2Non-AIDS defining events pancreatitis, grade 3 or 4 hepatic encephalopathy or liver-related death, myocardial 
infarction, stroke, coronary artery bypass graft, coronary angioplasty, carotid endarterectomy (grouped together as 
serious CV events), and end-stage renal disease (16).  NADMs were excluded. 
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Table 2 Malignancies classified as infection related (IRM) and unrelated (IURM) malignancies 
Malignancies N 
Infection related Malignancies (IRM) 388 
  Epstein-Barr virus (EBV) 159 
    
Non-Hodgkin lymphoma 
(NHL) 
116 
    Hodgkin lymphoma (HL) 43 
      
  
Hepatitis B and C viruses (HBV and 
HCV) 
 
    Liver 33 
      
  Human herpesvirus-8 (HHV8)  
    Kaposi’s sarcoma (KS) 62 
      
  Human papillomavirus (HPV) 123 
    Anal 83 
    Invasive cervical cancer (ICC) 33 
    Vulva and vagina 3 
    Penis 3 
   
Base of tongue, pharynx, 
tonsils 
1 
      
  H. pylori  
    Stomach 11 
Infection unrelated cancers (IURM) 255 
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    Lung 55 
    Prostate 28 
    Colorectal 23 
    Breast 22 
    Other 127 
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Table 3 Adjusted risk ratios (aIRR) and population attributable fractions (PAF%) of Infection related (IRM) and unrelated (IURM) malignancies 
Variable IRM     IURM   
    aIRR (95% CI) % Attributable P-
value 
  aIRR (95% CI) % Attributable  p-
value 
Age               
  <=35 years 1.34(0.90,2.01)  0.15   0.33(0.12,0.96) -3.1(-11.9,-0.1) 0.04 
  36 - 40 years ref ref .   ref ref . 
  41 - 50 years 1.34(0.97,1.85)  0.07   2.37(1.31,4.27) 16.5(6.9,21.9) <.01 
  51 + years 1.62(1.14,2.30) 12.3(3.9,18.2) <.01   7.33(4.07,13.21) 55.9(48.8,59.8) <.01 
Calendar year 1.01(0.97,1.05)   0.55   1.00(0.96,1.04)   0.95 
HIV-Viral Load >400 copies/mL 1.84(1.39,2.43) 19.3(11.8,24.9) <.01   0.91(0.62,1.35)  0.66 
CD4 cells/mm³               
  <200 3.77(2.59,5.51) 20.5(17.1,22.8) <.01   1.99(1.26,3.17) 6.3(2.6,8.6) <.01 
  200 - 349 1.83(1.35,2.48) 10.6(6.1,14.0) <.01   1.30(0.89,1.88)  0.17 
  350 - 499 1.24(0.92,1.67)  0.16   1.29(0.95,1.75)  0.11 
  500 + ref ref -   ref ref - 
Prior AIDS event (excl ADM) 1.25(1.00,1.57)  0.05   0.85(0.64,1.14)  0.29 
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Prior ADM 1.41(1.02,1.96) 3.1(0.2,5.2) 0.04   0.92(0.57,1.49)  0.74 
Prior non-AIDS event (excl NADM)       1.36(0.88,2.10)  0.17 
Prior NADM         2.13(1.42,3.20)  <.01 
Hepatitis B [HBV] 1.70(1.24,2.32) 5.3(2.5,7.3) <.01   1.73(1.17,2.55) 5.0(1.7,7.2) <.01 
Hepatitis C [HCV] 0.77(0.56,1.06)  0.11   0.90(0.60,1.37)  0.62 
Transmission group1               
  Homosexual ref ref -   ref ref - 
  IDU (Male) 0.83(0.57,1.20)  0.32   0.97(0.57,1.64)  0.91 
  IDU (Female) 1.21(0.79,1.86)  0.39   0.91(0.46,1.80)  0.78 
  Heterosexual (Male) 0.54(0.38,0.78)  <.01   0.91(0.61,1.36)  0.64 
  Heterosexual (Female) 0.57(0.40,0.80)  <.01   1.25(0.86,1.83)  0.24 
Smoking status1        
  Never ref 0.25 -   ref ref - 
  Previous 0.78(0.51,1.19)  0.25   1.24(0.80,1.91)  0.34 
  Current 1.15(0.91,1.46)  0.24   1.56(1.17,2.08) 16.4(6.8,23.7) <.01 
ADM: AIDS-defining-malignancy NADM: non-AIDS-defining malignancy IDU: Injecting drug user. 1Missing category not shown.  
Models were adjusted for baseline (ethnicity, region, gender and mode of transmission[Homosexual, male IDU, female IDU, male heterosexual, female heterosexual, missing], BMI) and time-updated (age, calendar year, smoking status [current, previous, never, missing], 
current HIV-VL plasma levels  [400, >400 copies/mL], CD4 cell count [<200, 200 – 349, 350 – 499, ≥500 cells/mm3], prior HBV/HCV co-infection, prior ADM, prior AIDS-defining diagnoses [excluding ADM], prior NADM, prior non-AIDS-defining events [defined as 
cardiovascular, end-stage renal disease, liver failure and pancreatitis, excluding NADM]19, exposure to cART [ARV regimen containing at least 3 drugs from any class], and regimen according to intention to treat: PI- or NNRTI-based) variables 
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Figure 1 adjusted rate ratios (aRR) of Infection unrelated (IURM) for (A)  CD4 count and (B)  smoking status and of Infection related related 
(IRM) for (C)  CD4 count and (D)  smoking status in those aged <50 and ≥50 years.  
Models were adjusted for age, calendar year, gender, ethnicity, region of residence, mode of transmission, current smoking status, baseline hepatitis C and B 
status,  current  HIV-VL, cumulative time HIV-VL >400 copies/mL, current CD4, cumulative time CD4<200 cells/mm3, prior ADM, prior AIDS-defining diagnosis 
(excluding ADM), prior NADM, prior non-AIDS defining diagnosis (excluding NADM), treatment group, PI use, NNRTI use.  
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a.  Semi-annual crude incidence rate (IR) of IRM/1000 PYFU for those recruited before 2001 with 5 and 
10 year forecast. 
 
b.  Semi-annual crude incidence rate (IR) of IURM/1000 PYFU for those recruited before 2001 with 5 
and 10 year forecast 
 
 
Figure 2 Forecast crude incidence rate (IR) of infection related (IRM) and infection unrelated malignancies (IURM)/1000 PYFU for those 
recruited before 2001 
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Table 4 Forecasted incidences of crude infection related and infection unrelated malignancies in people enrolled in EuroSIDA before 1 January 2001 overall and within strata. 
Subgroups 
Incidence of Infection related malignancies  Incidence of Infection unrelated malignancies 
/1000 PYFU  /1000 PYFU  
Jul – Dec 2011 Forecast at 5 years % change  Jul – Dec 2011 Forecast at 5 years % change 
Overall 3.1 (1.5, 5.9) 2.2 (0.9, 4.3) -29%  4.1 (2.2, 7.2) 5.9 (3.2, 10.2) 44% 
baseline age (years)        
 < 50 3.3 (1.8, 5.8) 2.4 (1.1, 4.6) -27%  2.8 (1.0, 6.0) 4.4 (1.9, 9.2) 57% 
 ≥50 1.8 (0, 11.6) 0.7 (0.0, 7.0) -61%  10.4 (3.4, 28.8) 15.3 (5.1, 42.7) 50% 
Baseline CD4 (cells/mm3)        
 <350 4.3 (1.5, 10.2) 2.9 (0.8, 7.4) -33%  4.1 (0.6, 15.5) 5.6 (1.0, 20.5) 37% 
 ≥ 350 2.7(1.0, 5.7) 2.0 (0.6, 4.6) -26%  3.6 (1.0, 9.5) 5.2 (1.6, 13.5) 44% 
Risk group        
 Homosexual 3.1 (1.0, 7.0) 1.6 (0.3, 4.2) -48%  4.2(1.5, 9.9) 5.0 (1.8, 12.1) 19% 
 Heterosexual 3.8 (0.6, 13.7) 3.3(0.2, 14.1) -13%  2.6 (0.0, 11.7) 3.3 (0.2, 14.1) 27% 
 Injecting drug users 4.9 (1.0, 16.9) 4.9 (0.9, 17.1) 0%  3.4 (0.0, 22.1) 7.0 (0.5, 42.4) 106% 
Baseline smoking status       
 Smokers 4.2 (0.7, 14.8) 3.3 (0.4, 12.3) -21%  4.5 (0.3, 21.5) 8.0 (1.1, 36.4) 78% 
  Non- smokers 3.5 (0.7, 11.4) 2.6 (0.3, 9.2) -26%  1.7 (0.0, 10.6) 0.8 (0.0, 7.0) -53% 
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